Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population
- PMID: 7619672
- PMCID: PMC1365007
- DOI: 10.1111/j.1365-2125.1995.tb04452.x
Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population
Abstract
1. The metabolism of proguanil (PG) was studied by measuring PG, cycloguanil (CG) and 4-chlorophenylbiguanide (CPB) in plasma and urine samples after an oral 200 mg dose of PG hydrochloride administered to 14 extensive (EMs) and 10 poor hydroxylators (PMs) of S-mephenytoin of Indonesian origin. 2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h). 3. Plasma concentrations of CG, an active metabolite, could not be detected in all PMs, and those of CPB were sufficiently high to determine a time-course in only four PMs. Mean AUC(0,24 h) values of CPB were significantly (P < 0.05) lower in the PM (n = 4) than in the EM group (n = 14) (0.47 +/- 0.13 vs 0.88 +/- 0.50 (-0.14 to 0.96) micrograms ml-1 h). 4. Log10 percentage urinary recovery of 4'-hydroxymephenytoin correlated significantly (P < 0.05) with the t 1/2 (rs = -0.661) and AUC (rs = -0.652) of PG. 5. PG, CG and CPB were detectable in urine at 12 h in all subjects. Log10 percentage urinary recovery of 4'-hydroxymephenytoin correlated significantly (P < 0.01) with urinary PG/CG (rs = -0.876), PG/CPB (rs = -0.833) and PG/(CG + CPB) (rs = -0.831) metabolic ratios.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.Eur J Clin Pharmacol. 2003 Nov;59(8-9):611-4. doi: 10.1007/s00228-003-0665-4. Epub 2003 Sep 12. Eur J Clin Pharmacol. 2003. PMID: 13680037 Clinical Trial.
-
Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status.Am J Trop Med Hyg. 1996 Feb;54(2):189-96. doi: 10.4269/ajtmh.1996.54.189. Am J Trop Med Hyg. 1996. PMID: 8619446
-
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.Br J Clin Pharmacol. 1991 Jun;31(6):689-92. doi: 10.1111/j.1365-2125.1991.tb05594.x. Br J Clin Pharmacol. 1991. PMID: 1867963 Free PMC article.
-
The multiple dose pharmacokinetics of proguanil.Br J Clin Pharmacol. 1993 Jun;35(6):653-6. doi: 10.1111/j.1365-2125.1993.tb04197.x. Br J Clin Pharmacol. 1993. PMID: 8329294 Free PMC article.
-
Genetic polymorphism of S-mephenytoin 4'-hydroxylation.Psychopharmacol Bull. 1996;32(2):219-30. Psychopharmacol Bull. 1996. PMID: 8783891 Review.
Cited by
-
Estimation of polymorphisms in the drug-metabolizing enzyme, cytochrome P450 2C19 gene in six major ethnicities of Pakistan.Bioengineered. 2021 Dec;12(1):4442-4451. doi: 10.1080/21655979.2021.1955809. Bioengineered. 2021. PMID: 34308762 Free PMC article.
-
The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.Eur J Clin Pharmacol. 2005 Sep;61(8):573-82. doi: 10.1007/s00228-005-0969-7. Epub 2005 Jul 23. Eur J Clin Pharmacol. 2005. PMID: 16041597 Clinical Trial.
-
Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.Eur J Clin Pharmacol. 2003 Nov;59(8-9):611-4. doi: 10.1007/s00228-003-0665-4. Epub 2003 Sep 12. Eur J Clin Pharmacol. 2003. PMID: 13680037 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources